Up­start maps plans to build fi­bro­sis pipeline; FDA ex­tends re­view pe­ri­od for Lil­ly’s baric­i­tinib

• A group of aca­d­e­m­ic in­ves­ti­ga­tors in Toron­to, work­ing through MaRS In­no­va­tion, are spin­ning out new tech to launch a biotech start­up dubbed Fi­bro­cor in part­ner­ship with Ger­many’s Evotec. Launched with about $2.1 mil­lion in seed mon­ey, they’ll work on iden­ti­fy­ing a lead pro­gram for fi­bro­sis in 2018.

• The FDA will take some added time to re­view Eli Lil­ly’s ap­pli­ca­tion for baric­i­tinib. The phar­ma gi­ant has filed some added da­ta analy­sis on the rheuma­toid arthri­tis drug that reg­u­la­tors will need time to re­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.